{"id":"rituximab-dhap","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their destruction through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. DHAP, on the other hand, is a combination chemotherapy regimen that targets rapidly dividing cancer cells. The combination of rituximab and DHAP is used to treat certain types of non-Hodgkin lymphoma.","oneSentence":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while DHAP is a chemotherapy regimen that includes the drugs dexamethasone, high-dose cytarabine, and cisplatin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:22.465Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory non-Hodgkin lymphoma"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT05966233","phase":"PHASE2","title":"R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-01","conditions":"Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":""},{"nctId":"NCT06255704","phase":"PHASE2","title":"A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2024-03-15","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT00078949","phase":"PHASE3","title":"Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-08-27","conditions":"Lymphoma","enrollment":849},{"nctId":"NCT01805557","phase":"PHASE2, PHASE3","title":"Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-02-04","conditions":"Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":108},{"nctId":"NCT03837873","phase":"PHASE2","title":"DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-01-21","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma","enrollment":118},{"nctId":"NCT03892421","phase":"PHASE1, PHASE2","title":"Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"La Raza Medical Center","startDate":"2018-04-05","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":22},{"nctId":"NCT00137995","phase":"PHASE3","title":"R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-06","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":481},{"nctId":"NCT00921414","phase":"PHASE3","title":"Mantel Cell Lymphoma Efficacy of Rituximab Maintenance","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-09","conditions":"Mantle Cell Lymphoma","enrollment":299},{"nctId":"NCT02371161","phase":"PHASE2","title":"Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02","conditions":"Non Hodgkin Lymphoma","enrollment":135},{"nctId":"NCT01453205","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-02-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":187},{"nctId":"NCT02983097","phase":"PHASE1, PHASE2","title":"Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","status":"TERMINATED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2010-11","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant","enrollment":34},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870},{"nctId":"NCT03069248","phase":"PHASE2","title":"Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2000-06-01","conditions":"Follicular Lymphoma","enrollment":36},{"nctId":"NCT00005601","phase":"PHASE2","title":"Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-10","conditions":"Lymphoma","enrollment":58},{"nctId":"NCT01653067","phase":"PHASE2","title":"STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Mathias Witzens-Harig","startDate":"2012-09","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":88},{"nctId":"NCT02842931","phase":"PHASE3","title":"R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2015-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":300},{"nctId":"NCT02532192","phase":"PHASE1","title":"A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01014208","phase":"PHASE3","title":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":447},{"nctId":"NCT01534949","phase":"PHASE1","title":"Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial","status":"TERMINATED","sponsor":"Celltrion","startDate":"2012-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1},{"nctId":"NCT00209222","phase":"PHASE3","title":"Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-07","conditions":"Lymphoma, Mantle-Cell","enrollment":360},{"nctId":"NCT00384553","phase":"PHASE1, PHASE2","title":"Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma","status":"UNKNOWN","sponsor":"University of Magdeburg","startDate":"2004-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RITUXIMAB + DHAP","genericName":"RITUXIMAB + DHAP","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is an antibody that binds to the B-lymphocyte antigen CD20, classified as a binding agent. It has been studied in combination with DHAP (a chemotherapy regimen) for the treatment of Diffuse Large B-Cell Lymphoma, Lymphoma, Large-Cell, Diffuse, and Lymphoma, Mantle-Cell.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}